Exchange: NASDAQ·Updated 12:47 PM EDT
News
all
press releases
Is BioAge Labs, Inc. (BIOA) Stock Positioned for Growth With New Phase 2 Cardiovascular Study Initiation?
Is BioAge Labs, Inc. (BIOA) Stock Positioned for Growth With New Phase 2 Cardiovascular Study Initiation...
Yahoo! Finance: News
More News
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets PR Newswire NEW YORK, May 20, 2026 Cell therapies and precision biologics are driving new...
PR Newswire
A Unique Klotho-based Anti-Aging Therapy to Be Introduced at a Premier Longevity Forum: Inside Ava Bio's Cell-Based Platform Approach
A Unique Klotho-based Anti-Aging Therapy to Be Introduced at a Premier Longevity Forum: Inside Ava Bio's Cell-Based Platform Approach A Unique Klotho-based Anti-Aging Therapy to Be Introduced at a...
PR Newswire
BioAge Labs (NASDAQ:BIOA) Trading 8.6% Higher - Here's Why
BioAge Labs (NASDAQ:BIOA) Shares Up 8.6% - What's Next...
MarketBeat
Wall Street Zen Downgrades BioAge Labs (NASDAQ:BIOA) to Sell
Wall Street Zen downgraded BioAge Labs from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat
BioAge Labs Touts Phase 1 BGE-102 Data, Citing 86% hs-CRP Drop and Clean Safety Profile
BioAge Labs (NASDAQ:BIOA) executives outlined phase I results for its oral, brain-penetrant NLRP3 inhibitor BGE-102, highlighting what the company characterized as deep reductions in inflammatory...
MarketBeat
Has Amarin (AMRN) Outpaced Other Medical Stocks This Year?
Here is how Amarin (AMRN) and BioAge Labs, Inc. (BIOA) have performed compared to their sector so far this year.
Zacks
BioAge Labs (NASDAQ:BIOA) Stock Price Down 6.1% - Time to Sell?
BioAge Labs (NASDAQ:BIOA) Trading Down 6.1% - What's Next...
MarketBeat
BioArctic publishes the Annual Report and Sustainability Report for 2025
BioArctic publishes the Annual Report and Sustainability Report for 2025 BioArctic publishes the Annual Report and Sustainability Report for 2025 PR Newswire STOCKHOLM, April 21, 2026 STOCKHOLM...
PR Newswire
Wall Street Analysts Predict an 183.67% Upside in BioAge Labs, Inc. (BIOA): Here's What You Should Know
The mean of analysts' price targets for BioAge Labs, Inc. (BIOA) points to an 183.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
<
1
2
>

Advertisement|Remove ads.